Lonza announced that its Board of Directors has approved the appointment of Daniel Palmacci as President of its Cell & Gene Division. The appointment will be effective from 1 November 2022. Daniel takes over the role from Jean-Christophe Hyvert, who continues to serve as President of Lonza's Biologics Division.

Daniel joins Lonza Group with more than two decades of experience in the pharmaceutical industry, including senior positions at Novartis and Bayer Healthcare. He also brings a wealth of international experience, having previously held roles in Switzerland, Germany, Italy, India, Brazil, France and the US. Most recently Daniel served as Senior Vice President, Global Head of Technical Operations and Executive Committee member at MorphoSys.

In this role, he transformed the Technical Operations function with a focus on improving its commercialization capabilities. He also oversaw the digitalization and AI strategy of MorphoSys, with a view to accelerating clinical development. Daniel takes over leadership of Cell & Gene from Jean-Christophe Hyvert, enabling Jean-Christophe to increase his focus on his role as President of the Biologics Division.

The appointment builds on the recent achievements and ongoing growth of both Divisions under Jean-Christophe's leadership since January 2021. The expanded Executive Committee structure provides a dedicated President for each of Lonza's four Divisions, thereby maximizing the growth potential of each area of the business. Daniel holds a Masters in Chemistry and Process Engineering from Technical University Berlin, Germany.

He is relocating from Munich (DE) to Basel (CH), where Lonza is headquartered.